Theravance Biopharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Theravance Biopharma sits in the top decile of US sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count).
Theravance Biopharma: 38 sponsored US clinical trials, none currently recruiting.
Theravance Biopharma sponsors 38 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 31 completed. 5 of these trials are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Adults, Elderly Subjects, with 2 trials.
Top-decile sponsor footprint
Theravance Biopharma ranks in the top decile of sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
31 of 37 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
38 total, page 1 of 1
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
NCT05165485
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
NCT05091723
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
NCT04681079
Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects
NCT04688632
Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects
NCT04587713
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
NCT03920254
TD-0903 for ALI Associated With COVID-19
NCT04402866
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
NCT04200573
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT04095793
Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects
NCT04044339
Efficacy & Safety of TD-1473 in Ulcerative Colitis
NCT03758443
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT03829657
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT03750552
Multiple Dose Ethnobridging PK Study in Healthy Subjects
NCT03750565
Efficacy and Safety of TD-1473 in Crohn's Disease
NCT03635112
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
NCT03555617
Drug-Drug Interaction (DDI) Study for TD-9855
NCT03432793
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
NCT03408470
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
NCT02705755
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
NCT03103412
Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects
NCT02954263
TD-1473 for Active Ulcerative Colitis (UC)
NCT02818686
Single Ascending Dose Study of TD-1439 in Healthy Subjects
NCT02903095
Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects
NCT02709928
SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects
NCT02657122
Single Ascending Dose Study of TD-0714 in Healthy Subjects
NCT02639078
TD-6450 MAD Study in HCV Infected Subjects
NCT02116543
TD-6450 SAD and MAD in Healthy Subjects
NCT02022306
TD-9855 Mass Balance Study
NCT01924143
TD-1607 MAD Study in Healthy Subjects
NCT01949103
TD-1607 SAD Study in Healthy Subjects
NCT01791049
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
NCT01718938
Phase 2 Study of TD-9855 to Treat Fibromyalgia
NCT01693692
A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
NCT01644240
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01458340
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
NCT01401985
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
NCT00442832
How the Theravance Biopharma early-phase archive is shaped
38 indexed studies, none listed as recruiting (0% open); 31 completed (82%).
Phase mix: 5 late (III/IV) vs 32 early (I/II) (early-phase heavy).
Top condition: Healthy Adults, Elderly Subjects (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Theravance Biopharma: archived-pipeline peers nationwide
Peers matched on 38 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Theravance Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 38 archived trials
- Acerta Pharma · 38 trials · 0% recruiting
- Astex Pharmaceuticals · 38 trials · 0% recruiting
- Corewell Health West · 38 trials · 11% recruiting
- DePuy Orthopaedics · 38 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Theravance Biopharma page
38 registered trials is a research-attention snapshot, not an endorsement of Theravance Biopharma or any single study.
- None of Theravance Biopharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy Adults, Elderly Subjects is the condition Theravance Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Adults, Elderly Subjects trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Theravance Biopharma pipeline card: 38 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.